Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease

Luke Whiley a, Arundhuti Sen a, James Heaton b, Petroula Proitsi a, Diego García-Gómez c, Rufina Leung a, Norman Smith b, Madhav Thambisetty d, Iwona Kloszewkska e, Patrizia Meccoci f, Hilkka Soininen g, Magda Tsolaki h, Bruno Vellas i, Simon Lovestone a, Cristina Legido-Quigley a,*, on behalf of the AddNeuroMed Consortium

a Institute of Pharmaceutical Science and Institute of Psychiatry, King's College London, London, UK
b Waters Centre of Innovation, King's College London, London, UK
c Analytical Chemistry Department, University of Salamanca, Salamanca, Spain
d Clinical and Translational Neuroscience Unit, Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, MD, USA
e Department of Old Age Psychiatry and Psychiatric Disorders, Medical University of Lodz, Lodz, Poland
f Section of Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy
g Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland
h Third Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece
i Department of Internal and Geriatrics Medicine, Hôpitaux de Toulouse, Toulouse, France

ARTICLE INFO

Article history:
Received 24 May 2013
Accepted 3 August 2013
Available online 13 September 2013

Keywords:
Alzheimer's disease
Phosphatidylcholine
ApoE
Lipid
Plasma
Mild cognitive impairment
Addneuromed

ABSTRACT

Abberant lipid metabolism is implicated in Alzheimer's disease (AD) pathophysiology, but the connections between AD and lipid metabolic pathways are not fully understood. To investigate plasma lipids in AD, a multiplatform screen (n = 35 by liquid chromatography–mass spectrometry and n = 35 by nuclear magnetic resonance) was developed, which enabled the comprehensive analysis of plasma from 3 groups (individuals with AD, individuals with mild cognitive impairment (MCI), and age-matched controls). This screen identified 3 phosphatidylcholine (PC) molecules that were significantly diminished in AD cases. In a subsequent validation study (n = 141), PC variation in a bigger sample set was investigated, and the same 3 PCs were found to be significantly lower in AD patients: PC 16:0/20:5 (p = 0.001), 16:0/22:6 (p < 0.05), and 18:0/22:6 (p < 0.01). A receiver operating characteristic (ROC) analysis of the PCs, combined with apolipoprotein E (ApoE) data, produced an area under the curve predictive value of 0.828. Confirmatory investigations into the background biochemistry indicated no significant change in plasma levels of 3 additional PCs of similar structure, total choline containing compounds or total plasma omega fatty acids, adding to the evidence that specific PCs play a role in AD pathology.

© 2014 Elsevier Inc. All rights reserved.

1. Introduction

It is estimated that there are 24 million persons worldwide with Alzheimer's disease (AD), a figure that is expected to double every 20 years until at least 2040 (Mayeux and Stern, 2012). The size of the affected population and the nature of the disease poses a huge challenge to patient health and care organizations around the world. However, the full physiological mechanism of AD is yet to be fully elucidated, and there is thus a need to identify both disease-relevant pathways for targeted treatment as well as molecular markers to aid in clinical diagnosis and monitoring disease progression (Jack et al., 2011).

Previous research has indicated that lipid molecules play a role in AD, and these have frequently been reported at abnormal concentrations in AD tissue (Bradley et al., 2012; Mangialasche et al., 2012; Wang et al., 2012). Many of these prior studies were conducted using a targeted experimental design, in which known pathways of disease were investigated in a focused manner, based on previous hypotheses of disease pathogenesis. Such targeted approaches have provided evidence suggesting a link between AD and high-density lipoproteins (HDLs) and related proteins in plasma (Di Paolo and Kim, 2011; Han et al., 2011; Lovestone et al., 1996; Oresic et al., 2011; Thambisetty et al., 2010; Whiley and Legido-Quigley, 2011). In addition, the lipoproteins apolipoprotein E (ApoE) and apolipoprotein J (ApoJ) have been linked to AD via both genetic and proteomic studies.

* Corresponding author at: Institute of Pharmaceutical Science, King's College London, 5th Flr., Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK. Tel.: +44 0 20 7848 4722.
E-mail address: cristina.legido_quigley@kcl.ac.uk (C. Legido-Quigley).
method was applied to increased sample numbers. The method is able to detect techniques achieving higher specificity on the applied methodology, with certain combinations of techniques achieving higher specificities (Martin et al., 2007; Whiley et al., 2012).

Non-targeted analysis of AD has previously been reported (Greenberg et al., 2009; Han et al., 2011; Orešić et al., 2011). The majority of these previous studies focus on plasma samples, analyzed either by liquid chromatography–mass spectrometry (LC-MS) (Greenberg et al., 2009; Orešić et al., 2011) or direct infusion mass spectrometry (DIMS) (Han et al., 2011). Interestingly, the significant molecular features identified in these previous works were lipid molecules. One of these studies reported an increase in ceramide (CM16) levels and a decrease in sphingolipid (SP16) levels in the plasma of AD patients (Han et al., 2011). Another investigation identified a phosphatidylcholine (PC) (PC16:0/16:0, as 1 of a cluster of 3 metabolites thought to be predictive markers of AD development in individuals with mild cognitive impairment (MCI) (Orešić et al., 2011). The third example reported a number of bile acids (GCA, GDCA, and GCDCA) that significantly decrease in AD plasma (Greenberg et al., 2009). The latter publication went on to recommend further investigation into the lipid fraction of the AD metabolome.

With these previous results in mind, we developed a non-targeted lipidomics to investigate plasma lipid species in AD. In the study described here, an initial metabolite screen involving LC-MS and nuclear magnetic resonance (NMR) profiling was performed, and the resultant data were analyzed using multivariate statistical modeling. The results of this “screen” phase indicated that 3 lipid phosphatidylcholine molecules (PC16:0/20:5, PC16:0/22:6, and 18:0/22:6) significantly decrease in AD plasma compared to controls. We then performed a multiplex protocol “validation”, designed to both confirm the findings, as well as provide further biological reasoning regarding the changes observed. Fig. 1 illustrates the overall study design and the individual analytical stages incorporated into each phase (screen and validation).

2. Methods

2.1. Sample cohorts

Plasma for the 2 experimental phases (screen and validation) was collected from 2 clinical cohorts, the AddNeuroMed cohort and the King’s College London Dementia Case Register (DCR). Ethical approval was awarded for all cohorts in the corresponding centers of collection. The cohorts are described in full in the Supplementary Information section and are summarized in Supplementary Table S1. Further details regarding sample collection and the AddNeuroMed and DCR cohorts can be found elsewhere (Hye et al., 2006; Lovestone et al., 2009; Simmons et al., 2009; Thambisetty et al., 2010).

2.2. Procedures

The study was divided into 2 major sections, designated throughout as “screen” (the initial screening phase) and “validation” (the subsequent confirmatory phase).

2.2.1. Screen phase

The screen phase of the study used 2 analytical platforms (LC-MS and NMR) to perform non-targeted analysis. LC-MS analysis was completed in a cohort of 35 age- and sex-matched human plasma samples (10 AD, 10 MCI, 15 control) (Supplementary Table S1). A complete method description is provided in the Supplementary Information section (under the heading “Screen LC-MS”).

A separate set of 35 samples (13 AD, 12 MCI, 10 control) (Supplementary Table S1) was analyzed by 1H-NMR spectroscopy at 600.29 MHz using a Bruker Advance 600 spectrometer (Bruker Biospin, Coventry, UK). Standard 1D, Carr-Purcell-Meiboom-Gill spin-echo (CPMG), and J-resolved (JRES) spectra were acquired for metabolomics and metabolite measurements. Further details regarding sample preparation and analysis are described in the Supplementary Information.

2.2.2. Validation phase

Validation was completed in 3 parts. First, a comprehensive LC-MS lipidomics method was applied to a larger sample set to confirm the initial PC observations from the screen phase; then,

![Fig. 1. Experimental pipeline overview. Initially a typical liquid chromatography–mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) metabolite screen led to the identification of 3 phosphatidylcholine (PC) molecules that significantly decrease in individuals with Alzheimer’s disease (AD) compared to controls. This led to a comprehensive multiplex lipidomic analysis consisting of 3 major components. During NMR analysis of patient plasma, particular attention was focused on total choline-containing molecules, a vital component of the phosphatidylcholine molecules identified in the screen experimental section. LC-MS analysis of plasma fatty acids (arachidonic acid, docosahexaenoic acid, and eicosapentaenoic acid) was also conducted. Again, as with NMR analysis of choline species, these fatty acid species are components of phosphatidylcholine structures indentified in the screen experimental section. Finally, comprehensive lipidomic validation was conducted with a large sample cohort. Here a specially developed lipidomic LC-MS method was applied to increased sample numbers. The method is able to detect 3000 lipid markers from a single plasma extraction.](image-url)
دریافت فوری

امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات